Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

CVS Health Corp said on Wednesday it would administer Eli Lilly & Co's experimental antibody treatment to COVID-19 patients in their homes and in long-term care facilities through a U.S.

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

This data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents - in this ...

A Cornell-led collaboration has devised a potentially low-cost method for producing antibodies for therapeutic treatments. They've bioengineered bacteria with an overlooked enzyme that can attach ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to ...

Protinah, a new drug development company specializing in protein-protein interaction (PPI) big data, announced on November 5 that it has been selected ...

ADCs integrate monoclonal antibodies with cytotoxic payloads, offering new treatment options for NSCLC, including biomarker-selected and biomarker-agnostic patients. ADCs are composed of an antibody, ...

Antibody-based drugs often become too thick to be injected at high concentrations. Now, new research can explain why this happens—knowledge that could eventually lead to easily injectable medications.